Search

Background: Treatment for most cases of keratosis pilaris requires simple reassurance and general skin care recommendations. Many Asian patients find lesions due to pigmented keratosis pilaris to be cosmetically unappealing. Treatment of post-inflammatory hyperpigmentation using a 1064-nm Q-switched Nd:YAG laser with low fluence is reported., Objective: To investigate the efficacy of a novel Q-switched Nd:YAG laser for the treatment of pigmented keratosis pilaris in Asian patients., Methods: Ten patients with pigmented keratosis pilaris underwent five weekly treatments using a Q-switched Nd:YAG laser (RevLite(®); HOYA ConBio(®), Freemont, CA, USA) at 1064 nm with a 6-mm spot size and a fluence of 5.9 J/cm(2). Photographic documentation was obtained at baseline and 2 months after the final treatment., Results: Clinical improvement was achieved in all 10 patients with minimal adverse effects., Conclusion: For the treatment of keratosis pilaris, the use of a Q-switched Nd:YAG laser can be helpful for improving cosmetic appearance as it can improve pigmentation.

Background: There are few publications on the treatment options for facial pore size reduction. A focused therapy is needed., Objective: To evaluate the efficacy of selective photodynamic therapy (PDT) using an optic fiber for the size reduction of large facial pores., Methods: A series of five patients (skin phototypes IV-V) with large facial pores received two successive weekly treatments with an 810-nm diode laser using a fine optic fiber after indocyanine green (ICG) was applied selectively to enlarged pores. Patients were evaluated using digital photography at each treatment session, and at 3 months post-operation. Clinical assessment scores were determined at each treatment session and follow-up visit. Patient satisfaction surveys were obtained at the end of the study., Results: All five participants who completed the 3-month follow-up gave a subjective assessment of reduction of facial pore size. Modest to excellent improvement was achieved., Conclusion: This study demonstrates that treatment with pin-point PDT using an optic fiber is a well-tolerated and effective regimen for the reduction of facial pore size.

Background: RF-pulsed light with ELOS technology devices have recently been used to treat acne vulgaris in selected patients., Objective: To investigate the safety and efficacy of a combination of two kinds of device with ELOS technology for the treatment of acne., Methods: Ten patients with moderate acne were treated twice weekly for 4 weeks with the Aurora AC (Syneron Medical Ltd, Yokneam, Israel), a combination of pulsed light and RF energy. Immediately after Aurora AC treatment, all patients were treated weekly only on one facial half with the Matrix IR (Syneron Medical Ltd), a combination of fractional diode laser and RF energy. Photographic documentations were obtained at baseline, before each treatment session, and 1 and 3 months after the final treatment., Results: At 3 months after treatment, the mean lesion count was reduced by 38% (p<0.05) after eight treatments with the Aurora AC alone. With additional treatment with the Matrix IR, the mean lesion count was reduced by 61%., Conclusion: The combination of Aurora AC and Matrix IR was superior in reducing the acne lesion count, and in extending the length of the remission period.

Ablative laser resurfacing is an effective treatment for atrophic acne scars. However, it often induces complications such as edema, prolonged erythema, scarring and hyperpigmentation. Therefore, a new concept of laser treatment called fractional photothermolysis has been designed to create microscopic thermal wounds to achieve skin rejuvenation treatment of atrophic acne scars. This study was designed to prospectively evaluate the use of a technique similar to fractional photothermolysis using only the standard CO2 laser without the fractional laser device in the treatment of atrophic scars and demonstrates it as a safe, effective and economical treatment option. Clinical improvement was achieved in all 35 patients with minimal adverse effects.